"As we continue to expect EU regulatory approval in the first quarter of calendar year of 2022, we are very excited to continue to drive our commercial efforts globally. We look forward to partnering with our customers and creating economic and clinical value to revolutionize patient care,” said Manuel O. Méndez, Chief Executive Officer of Quotient.